FDA approves engineered cell therapy for treating rare sarcoma
The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for the treatment of adults with a rare soft tissue cancer called synovial sarcoma.
Afami-cel is the first engineered T cell therapy to receive FDA approval for a solid tumor cancer.
The clinical trial that resulted in the drug’s approval was led by Memorial Sloan Kettering Cancer Center (MSK) sarcoma specialist and immunotherapy expert Sandra D’Angelo, MD.
“This treatment offers an important new option for people with this rare cancer,” Dr. D’Angelo ...












